ESCaping rejection: A step forward for embryonic-stem-cell-based regenerative medicine.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24388169.
- Also identified by DOI 10.1016/j.stem.2013.12.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The use of human embryonic stem cells (hESCs) for regenerative medicine currently faces several hurdles, including immune rejection of transplanted cells. Now in Cell Stem Cell, Rong et al. (2014) describe a strategy to protect hESCs from immune rejection while avoiding systemic immunosuppression, potentially facilitating clinical implementation of hESC-based therapies.
Medical subject headings
- Cell Differentiation
- Cell- and Tissue-Based Therapy
- Embryonic Stem Cells
- Graft Rejection
- Immunosuppression Therapy